Double punch for B-cell lymphomas: CAR T-cell innovation boo

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

Related Keywords

San Diego , California , United States , Guangzhou , Guangdong , China , New Zealand , Zhaotai , Gansu , American , Peter Lai , Robert Weinkove , Hunan Zhaotai Medical Group , Malaghan Institute Clinical , Guangzhou Institute Of Biomedicine , Wellington Zhaotai Therapies , Malaghan Institute Of Medical Research , Wellington Zhaotai Therapies Limited , Malaghan Institute , American Society Of Hematology , Medical Research , American Society , Annual Meeting , Malaghan Institute Clinical Director , Principal Investigator Dr Robert , Guangzhou Institute , Hunan Zhaotai Medical , Wellington Zhaotai Therapies Limited Executive , Professor Carl June , Cell , Clinical Trial , Efficacy , Lymphoma , Ntigen , Flood , Dancer , Cart Cell , Chimeric Antigen Receptor , Ytokine , Ytokines , Mp , Hematology , Ntracellular , Reclinical , Eceptor , Research , Yndrome , T Cell , Technology ,